remove_red_eye 445 Views
#Critical Care #Emergency Medicine #Pathology and Lab Medicine #Public Health
Two monoclonal antibody treatments for Ebola were associated with a significantly lower mortality rate among patients with the virus in the Democratic Republic of the Congo, a randomized trial found.
The single monoclonal antibody MAb114 and triple monoclonal antibody REGN-EB3 delivered lower mortality rates after 28 days compared to the novel antiviral agent remdesivir in development for Ebola and compared with another triple monoclonal antibody, ZMapp, which showed promise in another trial. The findings were published in the New England Journal of Medicine.